To ask the Secretary of State for Health and Social Care, what assessment his Department has made of patient outcomes for those undergoing heroin detoxification using Buvidal compared to Methadone.
Answered on
18 March 2025
No assessment has been made on patient outcomes for those undergoing heroin detoxification using buprenorphine long-acting injection, branded Buvidal, compared to methadone specifically. The Office for Health Improvement and Disparities is currently undertaking analysis of National Drug Treatment Monitoring System data to look at the comparative outcomes between Buvidal and other opioid substitution treatment medicines generally, not just methadone. This work is currently incomplete.
Treatment decisions are taken between a person and their clinician to ensure the right option for them, and long-acting injectable buprenorphine, branded as Buvidal, oral buprenorphine, and methadone should be offered as part of a package of care, alongside the usual talking therapies and recovery support that can help people stay off drugs. Local authorities are responsible for commissioning drug and alcohol services according to local need, and this includes the provision of buprenorphine long-acting injections.